B. Riley Forecasts Altimmune’s Q2 Earnings (NASDAQ:ALT)

Altimmune, Inc. (NASDAQ:ALT – Free Report) – Equities research analysts at B. Riley boosted their Q2 2025 EPS estimates for Altimmune in a report issued on Wednesday, May 14th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings of ($0.26) per share for the quarter, up from their previous forecast of […]

Leave a Reply

Your email address will not be published.

Previous post Nextracker (NASDAQ:NXT) Price Target Raised to $65.00
Next post Kane Biotech (CVE:KNE) Shares Down 13.3% – Here’s Why